LENSAR to Hold Fourth Quarter and Full Year 2020 Financial Results and Business Update Conference Call on Wednesday, March 10, 2021

Rhea-AI Summary

LENSAR, Inc. (NASDAQ: LNSR) will announce its fourth quarter and full year 2020 financial results on March 10, 2021, before market open. A conference call and webcast will follow at 8:30 am ET that day to discuss the results and corporate updates. LENSAR specializes in advanced femtosecond laser systems for cataract treatments, incorporating proprietary technologies aimed at enhancing surgical efficiency and visual outcomes. Investors should note that forward-looking statements regarding the company's performance include inherent risks and uncertainties.

Positive

• Focus on advanced femtosecond laser technology for cataract treatment that enhances surgical efficiency.
• Plans to provide valuable corporate updates alongside financial results in the upcoming conference.

Negative

• None.

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2020 financial results will be released before market open on Wednesday, March 10, 2021. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Wednesday, March 10, 2021 to discuss the financial results and recent corporate highlights.

To participate by telephone, please dial (833) 312-1363 (Domestic) or (236) 712-2498 (International). The conference ID number is 1061836. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility by providing advanced imaging, simplified procedure planning, efficient design and precision.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company’s assets and business are disclosed under the heading “Risk Factors” contained in the Company’s Form 10 Registration Statement, as amended, filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005919/en/

FAQ

When will LENSAR release its financial results for Q4 and full year 2020?

LENSAR will release its financial results on March 10, 2021, before market open.

What time will the LENSAR conference call take place?

The conference call will occur at 8:30 am ET on March 10, 2021.

How can I access LENSAR's conference call?

Participants can dial (833) 312-1363 for domestic or (236) 712-2498 for international access, using conference ID 1061836.

What technologies does LENSAR's laser system employ?

LENSAR's laser system features proprietary technologies for improved visual outcomes, efficiency, and reproducibility in cataract surgery.